| Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature. | |
| | |
MedLine Citation:
|
PMID: 15603208 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature. |
| | |
Authors:
|
Miguel A Park; Gerald W Volcheck; Juan C Guarderas |
Related Documents
:
|
7593568 - Vertebral collapse in childhood leukemia. 16938568 - Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and compl... 19641858 - Chronic myeloid leukemia patient manifesting fatal hepatitis b virus reactivation durin... 3422168 - Tdt expression in acute myeloid leukaemia. haemopoietic immaturity or maturational asyn... 10811028 - Treatment of chyloperitoneum after extended lymphatic dissection during duodenopancreat... 1658118 - Pacinian corpuscle hyperplasia in the hand. |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Allergy and asthma proceedings : the official journal of regional and state allergy societies Volume: 25 ISSN: 1088-5412 ISO Abbreviation: Allergy Asthma Proc Publication Date: 2004 Sep-Oct |
Date Detail:
|
Created Date: 2004-12-17 Completed Date: 2005-02-22 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9603640 Medline TA: Allergy Asthma Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 345-7 Citation Subset: IM |
Affiliation:
|
Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects* Desensitization, Immunologic* Drug Eruptions / etiology, therapy* Exanthema / chemically induced*, therapy* Humans Male Middle Aged Piperazines / adverse effects* Pyrimidines / adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment ...
Next Document: UV radiation-induced immunosuppression and skin cancer.